Novavax NVAX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $596.34M-52.5% | $1.12B+64.7% | $1.06B+20.3% | $1.08B+9.2% | $1.25B+25.9% | ||
| $89.62M-43.2% | $73.04M-64.0% | $87.61M-72.7% | $126.73M-64.7% | $157.65M-57.3% | ||
| $506.72M-53.8% | $1.05B+119% | $977.05M+73.2% | $951.99M+51.5% | $1.1B+74.8% | ||
| 85%-2.5pp | 93.5%+23.2pp | 91.8%+28.0pp | 88.3%+24.6pp | 87.4%+24.5pp | ||
| $348.86M-10.0% | $342.32M-12.5% | $370.82M-17.9% | $359.71M-23.6% | $387.43M-33.6% | ||
| $138.17M— | $157.48M— | $201.7M— | $240.79M— | —— | ||
| $674.49M-20.0% | $670.68M-28.0% | $757.17M-36.2% | $727.23M-43.2% | $843.55M-39.5% | ||
| -$78.15M-119% | $452.8M+282% | $307.49M+202% | $351.49M+220% | $411.41M+203% | ||
| -13.1%-45.9pp | 40.3%+76.8pp | 28.9%+62.9pp | 32.6%+62.3pp | 32.8%+72.8pp | ||
| $21.73M+0.2% | $22.55M+12.3% | $24.31M+46.4% | $23.06M+51.4% | $21.69M+52.6% | ||
| $42.4M-9.5% | $40.63M+0.5% | $44.27M+15.6% | $51.02M+163% | $46.84M+173% | ||
| —— | $0-100% | $12.99M-66.7% | $25.97M0.0% | $38.96M+200% | ||
| -$86.19M-118% | $442.17M+350% | $350.68M+225% | $431.39M+249% | $488.52M+223% | ||
| $1.65M-83.2% | $1.87M-82.9% | $8.94M+74.5% | $8.56M+56.9% | $9.82M+216% | ||
| -$87.84M-118% | $440.3M+335% | $341.75M+220% | $422.82M+244% | $478.7M+220% | ||
| -14.7%-52.9pp | 39.2%+66.7pp | 32.1%+64.3pp | 39.2%+69.0pp | 38.1%+78.2pp | ||
| -$0.64-124% | $2.35+275% | $1.78+178% | $2.27+181% | $2.64+183% | ||
| -$0.54-118% | $2.74+321% | $2.11+196% | $2.60+197% | $3.03+197% | ||
| 675.9M+3.1% | 690.3M+11.7% | 669.4M+18.1% | 667.1M+30.8% | 655.7M+46.3% | ||
| 649.6M+4.5% | 647.4M+7.8% | 637.6M+16.1% | 635.3M+29.0% | 621.7M+43.4% | ||
| —— | $0-100% | $12.99M-66.7% | $25.97M0.0% | $38.96M+200% | ||
| $42.4M-9.5% | $40.63M+0.5% | $44.27M+15.6% | $51.02M+163% | $46.84M+173% | ||
| -$78.15M-119% | $452.8M+282% | $307.49M+202% | $351.49M+220% | $411.41M+203% | ||
| -$55.81M-112% | $480.41M+340% | $342.49M+234% | $392.61M+259% | $456.1M+229% | ||
| -$55.81M-112% | $480.41M+340% | $342.49M+234% | $392.61M+259% | $456.1M+229% | ||
| -9.4%-45.7pp | 42.8%+72.1pp | 32.2%+60.9pp | 36.4%+61.5pp | 36.3%+71.9pp | ||
| -$78.15M-119% | $452.8M+282% | $307.49M+202% | $351.49M+220% | $411.41M+203% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Novavax's revenue?
- Novavax (NVAX) generated $596.3M in revenue over the trailing twelve months, down 52.5% year over year.
- Is Novavax profitable?
- Novavax is not currently profitable: it reported a net loss of $87.8M over the trailing twelve months, a -14.7% net margin.
- What are Novavax's profit margins?
- Gross margin is 85.0% and operating margin is -13.1%, with a -14.7% net margin.
- What is Novavax's earnings per share?
- Novavax's diluted EPS over the trailing twelve months is $-0.64.
- Where does Novavax's income statement data come from?
- Every line is extracted from Novavax's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
